MTRC has released a White Paper "Evidence requirements for the creation of IVD reimbursement (NABM) codes in France"

Securing reimbursement for in vitro diagnostic (IVD) tests in France is a complex, multi-year process - often taking between 3 to 5 years. Reimbursable in vitro diagnostic tests (IVD) tests should be included in the Nomenclature des Actes de Biologie Médicale (NABM). Each test has a nationally defined cost weight, which can be translated into reimbursement amounts. These tariffs are used mainly to reimburse IVD tests performed in outpatient settings.

In a recent White Paper, MTRC has analysed three actual HAS assessments - two favourable and one negative - to identify how evaluators interpret evidence and what factors influence reimbursement decisions most.

By dissecting these cases, the White Paper sheds light on the broader evidence requirements and decision-making framework used by HAS, offering diagnostics manufacturers critical insights into the expectations and potential challenges of securing NABM reimbursement.

Read more and request a White Paper here.